\nPfizer Inc. (NYSE: PFE) today announced the pricing of a sustainability bond of $1,000,000,000 in aggregate principal amount of 1.750% senior notes due 2031.\n<\/p>\n
\nThe closing of the offering is expected to occur on August 18, 2021, subject to satisfaction of customary closing conditions.\n<\/p>\n
\nPfizer intends to use the net proceeds to finance or refinance, in whole or in part as follows: research and development expenses related to COVID-19 vaccine research and development, capital expenditures in connection with the manufacture and distribution of COVID-19 vaccines and other projects of Pfizer or any of its subsidiaries that have environmental and\/or social benefits.\n<\/p>\n
\nCitigroup Global Markets Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC are acting as joint book-running managers for the offering.\n<\/p>\n
\nThis offering is being made pursuant to an effective shelf registration statement and prospectus and a related preliminary prospectus supplement filed by Pfizer with the Securities and Exchange Commission (the \u201cSEC<\/span>\u201d). Before you invest, you should read the prospectus and the related preliminary prospectus supplement, the registration statement and other documents that Pfizer has filed with the SEC for more complete information about Pfizer and this offering.\n<\/p>\n \nCopies of the prospectus supplement and related prospectuses for this offering can be obtained from Citigroup Global Markets Inc. toll-free at (800) 831-9146, from Goldman Sachs & Co. LLC, toll-free at (866) 471-2526; from J.P. Morgan Securities LLC, toll-free at (866) 803-9204, and from Morgan Stanley & Co. LLC, toll-free at (866) 718-1649.\n<\/p>\n \nThis press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, including the Notes. There shall not be any sale of the securities described herein in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.\n<\/p>\n About Pfizer: Breakthroughs That Change Patients\u2019 Lives <\/b><\/i><\/p>\n \nAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us.\n<\/p>\n Disclosure Notice<\/i><\/b>: This press release contains forward-looking statements made within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements involve substantial risks and uncertainties and potentially inaccurate assumptions. We have tried, wherever possible, to identify such statements by using words such as \u201cwill,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201clikely,\u201d \u201congoing,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cassume,\u201d \u201ctarget,\u201d \u201cforecast,\u201d \u201cguidance,\u201d \u201cgoal,\u201d \u201cobjective,\u201d \u201caim,\u201d \u201cseek\u201d and other words and terms of similar meaning or by using future dates in connection with any discussion of, among other things, the intended use of proceeds of the offering, Pfizer\u2019s anticipated operating and financial performance, reorganizations, business plans and prospects, expectations for Pfizer\u2019s product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, clinical trial results and other developing data that become available, revenue contribution, growth, performance, timing of exclusivity and potential benefits, strategic reviews, capital allocation objectives, dividends and share repurchases, plans for and prospects of Pfizer\u2019s acquisitions, dispositions and other business development activities, and Pfizer\u2019s ability to successfully capitalize on these opportunities, sales, expenses, interest rates, foreign exchange rates and the outcome of contingencies, such as legal proceedings, expectations for impact of or changes to existing or new government regulations or laws, Pfizer\u2019s ability to anticipate and respond to macroeconomic, geopolitical, health and industry trends, pandemics, acts of war and other large-scale crises and manufacturing and product supply.<\/i><\/p>\n In particular, forward-looking information in this press release includes statements relating to specific future actions and effects, including, among others, Pfizer\u2019s efforts to respond to COVID-19, including its development of a vaccine to help prevent COVID-19.<\/i><\/p>\n A list and description of risks, uncertainties and other matters can be found in Pfizer\u2019s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned \u201cRisk Factors\u201d and \u201cForward-Looking Information and Factors That May Affect Future Results\u201d, as well as in its subsequent reports on Form 8-K, and in the prospectus supplement and accompanying prospectus for the offering, in each case including in the section thereof captioned \u201cRisk Factors.\u201d You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider any such list to be a complete set of all potential risks or uncertainties. <\/i><\/p>\n We cannot guarantee that any forward-looking statement will be realized. Achievement of anticipated results is subject to substantial risks, uncertainties and inaccurate assumptions. Should known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. You should bear this in mind as you consider forward-looking statements, and you are <\/i>cautioned not to put undue reliance on forward-looking statements. We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law or by the rules and regulations of the SEC. You are advised, however, to consult any further disclosures we make on related subjects in our Form 10-K, 10-Q and 8-K reports and our other filings with the SEC.<\/i><\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210816005723\/en\/<\/a><\/span><\/p>\n \nMedia Contact: Investor Contact: KEYWORDS:<\/b> United States North America New York<\/p>\n INDUSTRY KEYWORDS:<\/b> Biotechnology Infectious Diseases Health Pharmaceutical Clinical Trials<\/p>\n<\/p>\n
\n
Pamela Eisele
\n
+1 (212) 733-1226
\n
Pamela.Eisele@Pfizer.com<\/a><\/p>\n
\n
Christopher Stevo
\n
+1 (212) 733-0437
\n
Christopher.Stevo@Pfizer.com<\/a><\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20210816005723\/en\/1045874\/3\/Pfizer_Logo_Color_RGB_APPROVED.jpg\"){kind=logo}
<\/td>\n<\/tr>\n